Avant Changes Name to Celldex Therapeutics, Hires Marucci as Permanent CEO
Luke Timmerman9/29/08
Avant Immunotherapeutics said today it is changing its name to Celldex Therapeutics as part of the merger the two companies announced in the first quarter. The Needham, MA-based company (NASDAQ: AVAN) will change its ticker symbol to (NASDAQ: CLDX), starting Oct. 1. The company’s board also announced that Anthony Marucci, who has worked as interim CEO since May, has gotten the job on a permanent basis. Celldex is developing antibody drugs to deliver vaccines directly to their therapeutic targets.
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
